Project Grant R00AA031067
- This federal Project Grant award of $701,051 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The grant supports research to investigate the phenotypes and functions of distinct neutrophil populations in patients with severe alcohol-associated hepatitis (AH). Key objectives include: 1) Characterizing the transcriptomic profiles and functional roles of neutrophil subsets in AH using single-cell RNA sequencing; 2)...
- This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology...
- This federal Project Grant award of $227,844.00 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) supports research to elucidate the impact of chronic and excessive alcohol consumption on tumor suppressor genes and their role in the development of alcohol-related liver cancer. The project aims to use both candidate and systemic approaches to identify and characterize key tumor suppressor genes crucial in the pathogenesis of alcohol-related...
- This $177,736 Project Grant award was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) located in Massachusetts. The project aims to investigate the role of hepatokines, predominantly hepatocyte-secreted proteins, in the pathogenesis of alcohol-associated liver disease and alcohol-associated hepatitis. Specifically, the research will explore the involvement of the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $249,000.00 to East Tennessee State University to characterize acetaldehyde-protein adducts and their effects on lymphocyte function in alcohol-associated liver disease. The research aims to investigate how the ethanol metabolite acetaldehyde forms adducts on proteins, particularly albumin, and how this modulates the pathogenesis of...
- This federal Project Grant award of $3,182,397.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to the University of California, San Diego (UCSD). The grant aims to characterize the role of host gut proteases, particularly cathepsin B, and the immune response in alcohol-associated liver disease (ALD) in both a human cohort and a mouse model. The research seeks to determine how alcohol-mediated induction of...
- This Project Grant award of $123,045.00 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) supports research on the role of the TRAF3IP2 protein in the development of alcohol-related cardiomyopathy. The project will investigate whether alcohol-induced cardiac fibroblast activation, proinflammatory cytokine expression, and extracellular matrix changes are dependent on TRAF3IP2, and whether deleting the TRAF3IP2 gene prevents alcohol-induced...
This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs), supports research to determine the molecular mechanism by which the neutrophilic NCF1 gene and its downstream target miR-223 impact the pathogenesis of alcohol-associated liver disease (ALD). The $249,000 project, awarded to the Trustees of Indiana University, will investigate how neutrophils drive disease severity and mediate liver injury in ALD through the NCF1-induced oxidative stress pathway and regulation of miR-223 expression. The research aims to expand understanding of the signaling mechanisms in neutrophils and their role in ALD progression, with the goal of informing potential therapeutic interventions. The project period runs from September 2025 to August 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $249.0k | 9/12/25 |